Welcome to our dedicated page for INVO Fertility news (Ticker: IVF), a resource for investors and traders seeking the latest updates and insights on INVO Fertility stock.
INVO Fertility, Inc. (Nasdaq: IVF) generates news as a healthcare services fertility company focused on assisted reproductive technology (ART), clinic operations, and its INVOcell-enabled intravaginal culture (IVC) procedure. The news flow around IVF often reflects developments in its fertility clinic network, financing activities, and technology initiatives that support its mission to expand access to fertility care.
Investors and observers following IVF news can expect regular updates on clinic performance and growth, including revenue trends from its INVO Centers and IVF clinic, as well as commentary on organic growth drivers such as patient volume, telehealth expansion, and service offerings at locations like Wisconsin Fertility Institute. Earnings-related press releases have highlighted clinic revenue, product revenue from INVOcell, and adjusted EBITDA metrics, along with management’s narrative on operational progress.
Another key category of news involves acquisitions and strategic agreements. INVO Fertility has reported the acquisition of Wisconsin Fertility Institute and the signing of a definitive asset purchase agreement to acquire the non-clinical assets of Family Beginnings, a fertility clinic in Indiana, through its subsidiary INVO Centers LLC. Such announcements provide insight into the company’s efforts to build a broader network of fertility centers across the United States.
News items also cover capital markets and corporate actions, including private placements of common stock and warrants, registration statements on Form S-1 for resale of securities, and corporate actions such as the 1-for-8 reverse stock split effective November 28, 2025. These updates help investors understand changes in the company’s capital structure and financing arrangements.
Finally, technology and operational updates feature in IVF news, such as the partnership with Heidi Health to deploy an AI-powered scribe platform at Wisconsin Fertility Institute, telehealth launches, and patent developments for a modified INVOcell device. For a consolidated view of these developments, this news page offers a centralized feed of INVO Fertility’s latest press releases and related disclosures.
INVO Fertility (Nasdaq: IVF) reported Q3 2025 results on November 17, 2025, showing continued top-line growth but ongoing losses. Revenue was $1.757M, up 23% YoY; consolidated clinic revenue rose 21% YoY to $1.722M, and revenue from all clinics was $1.995M, up 18% YoY. The company reported a net loss of $2.6M versus a $1.6M loss a year earlier, and Adjusted EBITDA of $(947,568), roughly flat year-over-year.
Operational highlights include 23% organic clinic growth, 130% YoY INVOcell device revenue growth, expanded telehealth and marketing initiatives, an acquisition pipeline, and efforts to improve clinic efficiencies and integrate AI scribe technology.
INVO Fertility (Nasdaq: IVF) announced on October 27, 2025 a strategic partnership with Heidi Health to deploy Heidi’s AI-powered scribe at the Wisconsin Fertility Institute (WFI) in Middleton, Wis.
The integration will work with existing EHR systems to automate clinical documentation in real time, producing notes, case histories and follow-ups. Heidi is reported to support nearly 2 million patient interactions per week, operate in 50+ countries across 200 specialties and in over 110 languages. Heidi claims the scribe automates an average of over two hours of daily administrative work and can reduce manual note-taking by up to 80%, aiming to free clinicians for patient care and reduce burnout. Patients can learn more at www.wisconsinfertility.com or call 608-824-0075.
INVO Fertility (NASDAQ: IVF), a healthcare company focused on expanding access to advanced fertility treatments, has announced its participation in the virtual Lytham Partners Fall 2025 Investor Conference on September 30, 2025.
The company will deliver a webcast presentation at 5:00 p.m. ET and conduct one-on-one meetings with investors throughout the event. The presentation will be accessible through the conference website and will be available for replay after the event.
INVO Fertility (NASDAQ:IVF) reported its Q2 2025 financial results, achieving record quarterly revenue of $1.86 million, up 1% year-over-year. The company's consolidated clinic revenue from Atlanta and Madison locations increased 1% to $1.83 million, while total revenue including equity method clinics rose 2% to $2.19 million.
Key operational highlights include Wisconsin Fertility Institute's recognition on Newsweek's Best Fertility Clinics list, launch of telehealth capabilities, and addition of Platelet-Rich Plasma therapy services. The company received a patent allowance for its modified INVOcell device, extending protection through 2040. INVO completed the divestiture of NAYA Therapeutics, retaining a minority stake while refocusing on core fertility operations.
However, the company reported a net loss from continuing operations of $(3.2) million, compared to $(2.2) million in Q2 2024, with Adjusted EBITDA at $(587,230).
INVO Fertility (NASDAQ: IVF) has announced a 1-for-3 reverse stock split effective July 21, 2025, at 12:01 a.m. Eastern Time. The company's common stock will continue trading under the symbol "IVF" on the Nasdaq Capital Market with a new CUSIP number 44984F708.
Following the split, every 3 shares will be consolidated into 1 share, with fractional shares rounded up. The company's outstanding shares will decrease to approximately 928,272, and authorized shares will be adjusted to 1,388,888. The primary goal is to meet Nasdaq's minimum bid price requirement of $1.00 per share for continued listing, though compliance is not guaranteed.
INVO Fertility (NASDAQ: IVF) announced strategic enhancements to its INVOcell® technology program, including expanded clinical training support and improved pricing. INVOcell, the first FDA-cleared intravaginal culture system, offers a more natural fertility treatment alternative to traditional IVF with comparable pregnancy rates.
The company is strengthening its dual position as both a technology innovator and fertility clinic operator. Key features of INVOcell include using the woman's body as a natural incubator, demonstrated success rates comparable to conventional IVF, and increased accessibility for diverse family structures. The technology recently secured a new U.S. patent allowance and offers clinics improved operational efficiency.
INVO Fertility (Nasdaq: IVF) has announced the addition of Platelet-Rich Plasma (PRP) therapy to its fertility services at the Wisconsin Fertility Institute center. The treatment utilizes the body's own growth factors to stimulate uterine lining growth and ovarian rejuvenation, potentially improving implantation rates and ovarian response.
The therapy is specifically designed for women facing particular fertility challenges, including those with thin uterine lining, diminished ovarian reserve, and patients seeking alternatives before considering egg donation or surrogacy. Dr. Gretchen Collins, a double board certified OB/GYN and REI at Wisconsin Fertility Institute, notes that while PRP therapy remains experimental in fertility treatment, it has demonstrated success in other medical fields such as orthopedics and wound healing.
INVO Fertility (Nasdaq: IVF) has received a notice of allowance for a new patent extending protection of its modified INVOcell device through 2040. The patent (Application No. 16/949,960) covers a simplified design based on embryologist feedback, removing the separate microchamber in favor of a singular main chamber.
INVOcell is the world's first FDA-cleared intravaginal culture (IVC) system that enables fertilization and embryo development within a woman's body. The device, which delivers comparable pregnancy rates to traditional IVF, was first FDA-cleared in 2015 and received additional clearance in 2023 for an extended 5-day incubation period.